Compare · RPTX vs RUBY
RPTX vs RUBY
Side-by-side comparison of Repare Therapeutics Inc. (RPTX) and Rubius Therapeutics Inc. (RUBY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. RPTX focuses on Biotechnology: Pharmaceutical Preparations, while RUBY focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- RPTX is the larger of the two at $602.2M, about the same size as RUBY ($574.2M).
- RPTX has more recent analyst coverage (9 ratings vs 4 for RUBY).
- Company
- Repare Therapeutics Inc.
- Rubius Therapeutics Inc.
- Price
- $2.63-0.19%
- $0.09-26.81%
- Market cap
- $602.2M
- $574.2M
- 1M return
- +3.33%
- -
- 1Y return
- +79.25%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2018
- News (4w)
- 0
- 0
- Recent ratings
- 9
- 4
Repare Therapeutics Inc.
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, a proprietary drug discovery program for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.
Rubius Therapeutics Inc.
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Latest RPTX
- SEC Form EFFECT filed by Repare Therapeutics Inc.
- SEC Form 4 filed by Large owner Bvf Partners L P/Il
- Amendment: SEC Form SCHEDULE 13D/A filed by Repare Therapeutics Inc.
- Director Rhoads Ann D returned 4,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Schafer Carol returned 8,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP, CHIEF FINANCIAL OFFICER Forte Steve returned 56,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Civik Thomas returned 7,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SVP, Finance and CAO Alves Sandra Isabelle Barros returned 31,622 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form S-8 POS filed by Repare Therapeutics Inc.
- SEC Form S-8 POS filed by Repare Therapeutics Inc.
Latest RUBY
- SEC Form 15-12G filed by Rubius Therapeutics Inc.
- SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)
- Rubius Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 25 filed by Rubius Therapeutics Inc.
- SEC Form DEF 14A filed by Rubius Therapeutics Inc.
- Stocks That Hit 52-Week Lows On Monday
- Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket